FDA Clears Pediatric CNS Cancer Trial for Lantern Pharma's STAR-001

Event summary

  • FDA cleared the Investigational New Drug (IND) application for STAR-001 in a Phase 1 pediatric clinical trial (IND No. 179145).
  • The trial will evaluate STAR-001 as a single agent and in combination with spironolactone in pediatric patients with relapsed or refractory CNS malignancies.
  • The study will be conducted across approximately 15 leading academic pediatric oncology centers in collaboration with POETIC.
  • STAR-001 targets ERCC3, a DNA repair enzyme, and spironolactone degrades ERCC3, enhancing DNA damage in cancer cells.

The big picture

Lantern Pharma's FDA clearance for STAR-001 marks a significant step in addressing a critical unmet need in pediatric neuro-oncology. The trial's focus on relapsed or refractory CNS malignancies, including aggressive tumors like DIPG and ATRT, highlights the potential for AI-driven drug discovery to identify novel therapeutic strategies. The collaboration with POETIC ensures broad access to a diverse patient population, which could accelerate the development timeline and enhance the trial's outcomes.

What we're watching

Trial Execution
Whether Lantern Pharma can successfully enroll and conduct the Phase 1 trial across multiple centers.
Regulatory Pathway
The pace at which the trial progresses and potential FDA feedback on the combination therapy approach.
Commercial Potential
How the trial results could position STAR-001 in the competitive landscape of pediatric CNS cancer treatments.

Related topics

Biotechnology